Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129740 · ClinicalTrials.gov registry record · Phase 2
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
A Phase 2 study of Leukemia, Myelogenous, Chronic, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 1
- Study location
NCT00129740 is a Phase 2 study of Leukemia, Myelogenous, Chronic that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 148 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00129740, a Phase 2 study of Leukemia, Myelogenous, Chronic, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if an experimental agent, AMN107 (nilotinib), can help to control CML in chronic phase. The safety of this experimental agent will also be studied.
Conditions Studied
Interventions
- DRUG Nilotinib
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2005-06-27 |
| Est. Completion | 2018-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129740
The ClinicalTrials.gov registry entry for NCT00129740 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myelogenous, Chronic appearing as the primary indexed condition, and to 1 intervention - of which Nilotinib is the first listed.
NCT00129740 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00129740 about?
NCT00129740 is a clinical study titled "Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)". The goal of this clinical research study is to learn if an experimental agent, AMN107 (nilotinib), can help to control CML in chronic phase. The safety of this experimental agent will also be studied.
What is the current status of trial NCT00129740?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2005-06-27. Estimated completion is 2018-07-11.
What conditions does trial NCT00129740 study?
This clinical trial studies the following conditions: Leukemia, Myelogenous, Chronic.
What interventions are being tested in trial NCT00129740?
The interventions under investigation include: Nilotinib (DRUG).
Who is sponsoring clinical trial NCT00129740?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00129740 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myelogenous, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.